‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

Published Date: 24 Apr 2026

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Read Full News

Latest News

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Germline Variants Predict Lobular Breast Cancer Recurrence

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

Todays Updates

Buprenorphine XR Injections Cut 'Need-Based' Opioid Craving

Extended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.

Fatty Pancreas Linked to Risk for T2D and CKD

Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.

Todays Updates

Buprenorphine XR Injections Cut 'Need-Based' Opioid Craving

Extended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.

Fatty Pancreas Linked to Risk for T2D and CKD

Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.

Latest News

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

News All Time

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Combination Treatment May Improve Multiple Myeloma Outcomes

Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.

Inside the Major Findings From the NHS-Galleri Trial

The largest randomized study of a multicancer blood test found no reduction in late-stage cancers, while raising new questions about stage shift, mortality benefit, and population screening.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.

The Growing Role of AI in Cancer Treatment

Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Pain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.

Capivasertib Wins Metastatic Prostate Cancer Approval

The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.

PSA Screening May Modestly Curb Prostate Cancer Deaths

New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Recommended News For You

Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

A promising medication could slow brain tumors in children.

ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Recommended Articles For You

The Impact of Microadenoma on Hormonal Health 

Finding Support: Connecting with the Vitiligo Community 

Demystifying Hypereosinophilic Syndrome: Symptoms, Diagnosis, and Treatment Options  

Radiation in Oncology: Advances, Applications, and Accessibility 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation

2.

a brand-new generic therapy for different types of cancer.

3.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

4.

Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.

5.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

1.

Beyond Symptoms: The Predictive Promise of Targeted Radionuclide Therapy in Palliative Oncology

2.

Botulinum Toxins in Oncology: A New Frontier in Chronic Pain Management and Apoptosis Induction

3.

How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?

4.

ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection

5.

Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

3.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

4.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot